Advances of Notch signaling regulating fetal liver stem/progenitor cells: implications for the therapy of end-stage liver diseases
10.3760/cma.j.issn.1007-8118.2014.01.019
- VernacularTitle:Notch信号通路调控胎肝干/祖细胞治疗终末期肝病的研究进展
- Author:
Qike HUANG
;
Nan YOU
;
Lili DANG
;
Guangxin LIU
;
Kaishan TAO
- Publication Type:Journal Article
- Keywords:
Fetal liver stem/progenitor Cells (FLSPCs);
Cell therapy;
End-stage liver diseases (ESLDs);
Notch signaling pathway
- From:
Chinese Journal of Hepatobiliary Surgery
2014;20(1):66-69
- CountryChina
- Language:Chinese
-
Abstract:
Cell therapy has a very promising potential for end-stage liver diseases (ESLD).Fetal liver stem/progenitor cells (FLSPCs) have advantages of safety,high survival and proliferation rates,and a small volume,all which make them ideal for liver disease stem cell therapy.During the early phase of our study,we applied a three-step separation method to enrich FLSPCs and obtained a separation efficiency similar to that of the flow-cell sorting method.Additionally,using a fulminant hepatic failure model in rats,we have demonstrated that FLSPCs can contribute to morphological and functional recovery of the liver.This manuscript will discuss how FLSPCs can be induced to accurately differentiate into hepatocytes and cholangiocytes and how FLSPCs maintain self-renewal.The Notch signaling plays a critical role in regulating the differentiation and self-renewal of many types of stem cells.Our previous findings have shown that the Notch signaling plays an important role in FLSPCs differentiation into hepatocytes.Therefore,the Notch signaling might be involved in the differentiation and self-renewal of FLSPCs.We conducted a study on the regulatory effects and relative molecular mechanisms of the Notch signaling on FLSPCs and found the corresponding interfering target,which might become an index for the clinical application of FLSPCs.
